Co-Afaris Paed 75/50/150 75mg. 50mg. 150mg Tablet
PDF Leaflet Revision Date: 26 October 2018
Clinical Summary
Quick overview from the medicine insert
Indication
Pulmonary tuberculosis in children.
Dosage (summary)
5 days/week; 15 mg/kg rifampicin, 10 mg/kg isoniazid, 35 mg/kg pyrazinamide.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety not established; crosses placenta and excreted in breastmilk.
Key Drug Interactions
- Nevirapine
- Saquinavir
- Ritonavir
- Alcohol
Contraindications
- Hypersensitivity to rifamycins
- Jaundice
- Hepatic impairment
Common side effects
- Nausea
- Vomiting
- Hepatitis
- Peripheral neuropathy
Counselling Points
- May cause urine discoloration
- Avoid alcohol
- Monitor for hepatitis symptoms
Serious warnings
- Severe hepatotoxicity
- Monitor liver function
Important Disclaimer
The Co-Afaris Paed 75/50/150 75mg. 50mg. 150mg Tablet professional information leaflet below is the property of Macleods Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
